Endofotonics logo

Endofotonics

Identifying Early-stage Cancers Through In vivo Molecular Diagnosis

4 employees · est. 2013 · Singapore, Singapore

VS
Lucence logo

Lucence

Overcoming cancer through earlier detection

111 employees · est. 2016 · Palo Alto, United States

Endofotonics is the older company (2013 vs 2016); Lucence is the larger of the two.

Side-by-Side Comparison

Endofotonics Lucence
Founded
2013 older 2016
Headquarters
Singapore, Singapore Palo Alto, United States
Employees
4 111 larger
Industry
Biotechnology, Health Care, Information Technology Biotechnology, Health Care
Funding Stage
Series B Series A
Total Funding
$9.06M $29.20M
Funding Rounds
3 3
Services
Not tracked yet LiquidHALLMARKse, LucenceINSIGHTse, CardioHemeRISK19, LucenceLONGEVITY19, HemeMARK19, UNITED 600, UNITED CNS, Rapid TissueMARK19, LucenceMONITOR19
Target Customers
Not tracked yet Oncologists, Primary Care Doctors, Patients, Insurers, Investors
Taxonomy
Medtech, Raman Spectroscopy, Cancer Detection, In-vivo Diagnosis, Gastric Cancer, Early-stage Detection, Biomedical Technology, Optics, Medical Devices, Advanced Manufacturing, Endoscopy, Spectroscopy Platform, Series B Funding, Asia Pacific Commercialization, Lean Team Precision Health, Liquid Biopsy, AI-powered Technology, Cancer Detection, Personalized Cancer Care, Early Cancer Detection, Targeted Cancer Treatment, Proprietary Technology, Medical Diagnostics, CLIA-licensed Laboratories, Healthcare Innovation, Cancer Screening
Website
endofotonics.com lucence.com
Endofotonics logo

About Endofotonics

Endofotonics is a medtech organisation dedicated to using its proprietary Raman spectroscopy platform technology to improve early cancer detection and reduce cancer burden in patients. Founded in 2013 and headquartered in Singapore with a subsidiary in Shanghai, China, the company developed the SPEC...

Lucence logo

About Lucence

Lucence, founded in 2016, is a pioneering venture in the Biotechnology and Health Care industries. The company stands out with its mission of Overcoming cancer through earlier detection. By leveraging proprietary AI-powered liquid biopsy technology, Lucence aims to detect cancers at an earlier stage...

We will tell you when either one moves

BounceWatch watches Endofotonics and Lucence for new funding, fast hiring, new executives and a change of software vendor. When one happens, we email you the same day.

Watch both — free

Funding, hiring, leadership and stack changes at Endofotonics and Lucence — by email.

Frequently Asked Questions

Endofotonics — Identifying Early-stage Cancers Through In vivo Molecular Diagnosis. Lucence — Overcoming cancer through earlier detection. Both companies operate in related markets but may differ in funding stage, team size, and product focus.
Endofotonics has raised $9.06M while Lucence has raised $29.20M.
Endofotonics and Lucence operate in overlapping markets and are frequently compared. Track both companies on Bounce Watch to monitor their growth signals in real time.

Compare Endofotonics with someone else

Start typing a company name or domain.

Related Comparisons

Compiled from the BounceWatch company index. We last looked at Endofotonics on 12 Sep 2024, and Lucence on 15 Jun 2026. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.

One analytics cookie (Google Analytics). Cookie Policy